Interpace Diagnostics Group (IDXG) Posts Earnings Results, Misses Estimates By $0.03 EPS

Interpace Diagnostics Group (NASDAQ:IDXG) issued its quarterly earnings data on Monday. The business services provider reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.03), Morningstar.com reports. Interpace Diagnostics Group had a negative return on equity of 33.16% and a negative net margin of 55.67%. Interpace Diagnostics Group updated its FY 2019 guidance to EPS.

Shares of IDXG stock opened at $0.71 on Tuesday. The company has a market capitalization of $28.58 million, a price-to-earnings ratio of -1.65 and a beta of 2.50. Interpace Diagnostics Group has a fifty-two week low of $0.67 and a fifty-two week high of $1.78.

Hedge funds have recently modified their holdings of the business. Northern Trust Corp increased its holdings in Interpace Diagnostics Group by 27.4% in the first quarter. Northern Trust Corp now owns 88,246 shares of the business services provider’s stock worth $70,000 after purchasing an additional 19,001 shares in the last quarter. Virtu Financial LLC increased its holdings in Interpace Diagnostics Group by 18.4% in the fourth quarter. Virtu Financial LLC now owns 89,036 shares of the business services provider’s stock worth $71,000 after purchasing an additional 13,846 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Interpace Diagnostics Group in the third quarter worth approximately $194,000. Essex Investment Management Co. LLC increased its holdings in Interpace Diagnostics Group by 12.4% in the fourth quarter. Essex Investment Management Co. LLC now owns 339,678 shares of the business services provider’s stock worth $272,000 after purchasing an additional 37,506 shares in the last quarter. Finally, Perkins Capital Management Inc. increased its holdings in Interpace Diagnostics Group by 86.4% in the first quarter. Perkins Capital Management Inc. now owns 1,922,250 shares of the business services provider’s stock worth $1,538,000 after purchasing an additional 891,250 shares in the last quarter. Institutional investors and hedge funds own 14.40% of the company’s stock.

A number of brokerages have recently issued reports on IDXG. Maxim Group restated a “buy” rating and set a $4.00 price objective on shares of Interpace Diagnostics Group in a research report on Wednesday, March 20th. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Interpace Diagnostics Group in a research report on Wednesday, February 20th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Interpace Diagnostics Group currently has a consensus rating of “Buy” and a consensus target price of $2.90.

WARNING: This piece of content was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/14/interpace-diagnostics-group-idxg-posts-earnings-results-misses-estimates-by-0-03-eps.html.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

Recommended Story: Different Options Trading Strategies

Earnings History for Interpace Diagnostics Group (NASDAQ:IDXG)

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.